Skip to main content
BBIO
NASDAQ Life Sciences

BridgeBio的BBP-418对LGMD2I/R9的第三期试验结果强劲，2026年上半年计划提交NDA

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$71.39
Mkt Cap
$13.84B
52W Low
$28.325
52W High
$84.94
Market data snapshot near publication time

summarizeSummary

BridgeBio Pharma宣布其BBP-418在患有肢带肌营养不良症2I/R9（LGMD2I/R9）的患者中进行的第三期FORTIFY临床试验的中期分析结果非常积极。数据表明了一致的疗效，包括早期和持续的行走能力改善和血清肌酸激酶减少，并伴有与安慰剂相似的有利安全性特征。这些具体的BBP-418第三期试验的积极数据提供了公司最近在10-K中关于管道药物积极的第三期数据和计划于2026年进行的监管申报的总体声明的具体细节。公司现在计划在2026年上半年向FDA提交新药申请（NDA），并预计美国可能于2026年底或2027年初推出。如果获得批准，BBP-418可能成为首种用于治疗LGMD2I/R9的疗法，这代表着一个重大的商业机会和公司估值的重要催化剂。投资者现在将关注NDA提交时间表和随后的FDA审查过程。

在该公告发布时，BBIO的交易价格为$71.39，交易所为NASDAQ，所属行业为Life Sciences，市值约为$138.4亿。 52周交易区间为$28.33至$84.94。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed BBIO - Latest Insights

BBIO
Apr 24, 2026, 4:25 PM EDT
Filing Type: DEFA14A
Importance Score:
7
BridgeBio Pharma Seeks Shareholder Approval for 2 Million Share Increase in Equity Incentive Plan
Sentiment: Neutral
View Wiseek Article
BBIO
Apr 02, 2026, 6:40 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Viking Global Reduces BridgeBio Pharma Stake by $81M; Director Ott Retires
Sentiment: Negative
View Wiseek Article
BBIO
Mar 30, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
9
BridgeBio Submits NDA for BBP-418, Targeting First-Ever LGMD2I/R9 Therapy
Sentiment: Positive
View Wiseek Article
BBIO
Mar 30, 2026, 3:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Acoramidis Long-Term Data Reveals Near 50% Mortality Reduction in ATTR-CM
Sentiment: Positive
View Wiseek Article
BBIO
Mar 11, 2026, 2:00 PM EDT
Source: GlobeNewswire
Importance Score:
9
BridgeBio's BBP-418 Delivers Strong Phase 3 Results for LGMD2I/R9; NDA Filing Set for H1 2026
Sentiment: Positive
View Wiseek Article
BBIO
Feb 24, 2026, 4:51 PM EST
Filing Type: 10-K
Importance Score:
9
BridgeBio Pharma Reports Strong Attruby Commercial Performance, Advances Multiple Phase 3 Programs, and Secures New Convertible Debt
Sentiment: Positive
View Wiseek Article
BBIO
Feb 24, 2026, 4:04 PM EST
Filing Type: 8-K
Importance Score:
8
BridgeBio Reports Strong Q4/FY25 Results, Multiple Phase 3 Successes, and Key NDA Submissions
Sentiment: Positive
View Wiseek Article
BBIO
Feb 17, 2026, 8:46 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Viking Global Investors Reduces Stake Following Positive Clinical Data
Sentiment: Neutral
View Wiseek Article
BBIO
Feb 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib in Achondroplasia, Meeting Primary and Key Secondary Endpoints
Sentiment: Positive
View Wiseek Article
BBIO
Jan 21, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
BridgeBio Raises $632.5M via Convertible Notes, Refinances Debt, and Repurchases Shares
Sentiment: Positive
View Wiseek Article